Clinical evidence dossier
Hybrid closed-loop system
Time in range
Evidence signal
Evidence signal
Strong
This is an authoritative evidence signal supplied by Clinical Reference. It is not a formal clinical grade, treatment recommendation, or pooled effect estimate.
Evidence snapshot
- Authoritative support records
- 17
- Supporting studies available for review
- 17
- Randomized trials
- 16
- Reported effects
- 35
Clinical conclusion
Hybrid closed-loop system shows a moderate positive evidence signal for improving Time in range across the studied comparisons.
The conclusion and evidence-signal classification are distinct authoritative fields and are reproduced as published.
Observed effects
Observed study estimates; not a pooled treatment effect.
Change from baseline
Absolute change
61.2% to 61.2%
Between-group effect
Absolute change
−15.6% to 79.2%
Between-group effect
Absolute change
−15 percentage points to 15 percentage points
Between-group effect
Mean difference
−3.6% to 15.2%
Evidence composition
- Non-randomized studies
- 0
- Other designs
- 0
- Unresolved designs
- 1
- Magnitude-eligible effects
- 13
Consistency
Consistency classification
Mostly consistent
- Positive
- 9
- No effect
- 4
- Mixed
- 4
- Negative
- 0
Population and applicability
Structured population data were available for 17 of 17 supporting studies. Diabetes type was heterogeneous: 10 studies with type 1 diabetes, 2 studies with type 2 diabetes. Age groups were heterogeneous: 12 studies with adult participants, 1 studies with youth participants.
This population information refers to the materialized supporting studies available for review. Omitted support records remain part of the authoritative support accounting and are available through the audit experience.
View reported population descriptions
These descriptions are reported across the supporting studies; they are not a single synthesized population.
- Adults aged 18 and older with type 1 diabetes.
- Individuals currently managing diabetes with insulin therapy.
- Participants starting advanced hybrid closed-loop therapy.
- Young Adult (19–39)
- Middle Aged (40-64)
- Older Adults (65+)
- Male
- Female
- with T1 Diabetes
- Adults with diabetes and advanced chronic kidney disease.
- Individuals requiring insulin therapy.
- Women with Type 1 diabetes postpartum.
Limitations
- 4 supporting studies do not have a displayable topic-matched quantitative effect.
- Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, other, unknown_unresolved, usual_care.
- 1 supporting study has high, serious, critical, unclear, or unavailable risk-of-bias information.
- 1 study contains conflicting p-value and significance fields; those significance claims are suppressed.
Supporting evidence
Inspect the authoritative studies and omitted support records for this dossier.